Trajanje liječenja i razlozi prekida primjene TNF-alfa i IL-17 inhibitora u kohorti bolesnika s aksijalnim spondiloartritisom – iskustva jednog tercijarnog centraDraženka Kontek2024-02-05T15:38:09+01:00
COVID-19 COURSE AND OUTCOME IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES WHO ARE ON BIOLOGICAL OR TARGETED SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS – RESULTS FROM A SINGLE RHEUMATOLOGY CENTREDraženka Kontek2023-05-31T10:02:21+02:00
